{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Sheet1"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":47,"n_cols":9,"rows_kept":47,"merged":[[0,0,0,4],[1,2,1,4],[1,6,1,8],[46,0,46,8]],"flags":["formulas_cached_only"]}
["Table S3. Univariate analysis of factors associated with prognosis in the HGG group."]
[null,null,"Progression-free survival",{"$nulls":3},"Overall survival"]
["Clinicopathological features","No. of cases","Progression-free survival months (median, 95% CI)","P value","Hazard Ratio (median, 95% CI)",null,"Overall survival months (median, 95% CI)","P value","Hazard Ratio (median, 95% CI)"]
["LGR5 expression",null,null,0.018,"1.55 (1.05-2.30)",null,null,0.027999999999999997,"1.60 (1.04-2.44)"]
["    High",129,"7.0 (5.3-8.7)",{"$nulls":3},"17.5 (12.3-22.7)"]
["    Low",54,"10.5 (2.9-18.1)",{"$nulls":3},"23.0 (12.4-33.6)"]
[]
["Age",null,null,0.6070000000000001,"0.91 (0.63-1.32)",null,null,0.757,"0.94 (0.63-1.41)"]
["   ≧ 40",128,"8.0 (6.0-10.0)",{"$nulls":3},"21.0 (15.0-27.0)"]
["   < 40",55,"7.0 (5.2-8.8)",{"$nulls":3},"20.0 (14.4-25.7)"]
[]
["Gender",null,null,0.185,"1.27 (0.89-1.80)",null,null,0.444,"1.16 (0.80-1.68)"]
["    Male",108,"7.5 (5.9-9.1)",{"$nulls":3},"17.5 (11.5-23.5)"]
["    Female",75,"7.0 (4.6-9.4)",{"$nulls":3},"20.0 (14.8-25.2)"]
[]
["KPS",null,null,0.061,"0.72 (0.51-1.02)",null,null,0.029000000000000005,"0.67 (0.46-0.96)"]
["   ≧ 80",109,"8.5 (6.2-10.8)",{"$nulls":3},"24.0 (19.1-28.9)"]
["   < 80",74,"5.0 (2.8-7.2)",{"$nulls":3},"13.5 (6.6-20.4)"]
[]
["Location",null,null,0.152,"1.42 (0.87-2.31)",null,null,0.792,"0.94 (0.59-1.50)"]
["   Supratentorial",149,"7.5 (6.1-8.9)",{"$nulls":3},"16.0 (9.0-23.0)"]
["   Subtentorial",34,"12.0 (0.1-23.9)",{"$nulls":3},"20.0 (15.4-24.6)"]
[]
["Peritumoral edema",null,null,0.031000000000000003,"1.47 (1.03-2.11)",null,null,0.157,"1.31 (0.90-1.91)"]
["   Severe",103,"7.0 (5.5-8.5)",{"$nulls":3},"18.0 (11.5-24.5)"]
["   Slight/None",80,"8.5 (6.2-10.8)",{"$nulls":3},"21.0 (13.4-28.6)"]
[]
["Tumor size",null,null,{"v":0.1,"d":"0.100"},"1.33 (0.94-1.88)",null,null,0.085,"1.38 (0.95-2.00)"]
["   ≧ 3.5cm",97,"7.5 (5.7-9.3)",{"$nulls":3},"16.5 (11.9-21.1)"]
["   < 3.5cm",86,"7.5 (4.6-10.4)",{"$nulls":3},"22.5 (18.4-26.6)"]
[]
["Ki67",null,null,0.059,"1.39 (0.98-1.98)",null,null,{"v":0.22,"d":"0.220"},"1.26 (0.87-1.85)"]
["   ≧ 20%",68,"7.0 (5.0-9.0)",{"$nulls":3},"17.5 (12.3-22.7)"]
["   < 20%",115,"7.5 (5.4-9.6)",{"$nulls":3},"23.0 (16.4-29.6)"]
[]
["ATRX",null,null,0.187,"1.28 (0.88-1.86)",null,null,0.328,"1.22 (0.82-1.82)"]
["   Loss",52,"7.5 (2.9-12.2)",{"$nulls":3},"14.5 (6.0-23.0)"]
["   Expression",131,"7.5 (5.9-9.1)",{"$nulls":3},"21.0 (17.3-24.7)"]
[]
["IDH1",null,null,0.073,"0.68 (0.44-1.05)",null,null,{"v":0.01,"d":"0.010"},"0.53 (0.32-0.87)"]
["   MT",38,"12.0 (8.6-15.4)",{"$nulls":3},"31.0 (23.1-38.9)"]
["   WT",145,"6.5 (4.9-8.1)",{"$nulls":3},"16.5 (12.7-20.2)"]
[]
["Chemoradiotherapy",null,null,0.006,"0.59 (0.41-0.85)",null,null,{"v":0.03,"d":"0.030"},"0.65 (0.44-0.97)"]
["   Yes",65,"12.0 (5.9-18.1)",{"$nulls":3},"27.5 (19.9-35.1)"]
["   No",118,"6.5 (4.7-8.3)",{"$nulls":3},"16.0 (11.4-20.6)"]
["Abbreviation: HGG, high-grade glioma; LGR5, leucine-rich repeat-containing G protein-coupled receptor 5; KPS, karnofsky performance scale; ATRX, alpha thalassemia/mental retardation syndrome X-linked; IDH1, isocitrate dehydrogenase 1; CI, confidence interval."]